Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)

Complete title: A Phase 3, Multinational, Randomized, Open-Label, Parallel-Arm Study of Avelumab (MSB0010718C) in Combination with Axitinib (Inlyta) versus Sunitinib (Sutent) Monotherapy in the First-Line Treatment of Patients with Advanced Renal Cell Carcinoma

Research Study Number 20152576
 
Principal Investigator Scott Tykodi, MD
 
Phase III

Research Study Description

This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of avelumab in combination with axitinib and of sunitinib monotherapy, administered as first-line treatment, in patients with advanced renal cell carcinoma

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number 20152576
 
Contact Seattle Cancer Care Alliance Intake Office
 
Telephone 800-804-8824 / 206-606-1024
 

Keywords: Kidney Cancer; Renal Cancer; Solid Tumors; Neoplasms; Urogenital Neoplasms; Urologic Neoplasms; Neoplasms, Glandular and Epithelial; Immunotherapy

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials